Heptares moves to Welwyn BioPark and plans further expansion
Heptares’ CEO, Dr Malcolm Weir, said: “Heptares has progressed rapidly since 2007, and the new funds we raised earlier this year have given us a very good opportunity to implement our strategy for generating new drug candidates to highly validated but previously challenging GPCRs. We are pleased to move to the Welwyn BioPark, which provides a first-class research environment within easy reach of London and Cambridge, where we retain excellent scientific links.”
The Company’s new address as from 12 May 2008 is:
Heptares Therapeutics Ltd, BioPark, Broadwater Road, Welwyn Garden City, Hertfordshire, AL7 3AX
Most read news
Other news from the department business & finance
These products might interest you
Systec H-Series by Systec
Safe, reproducible and validatable sterilization of liquids, solids and waste
Autoclaves with 65-1580 liters usable space, flexibly expandable for various applications
Whatman™ folded filter papers by Cytiva
Whatman folded filter papers
Convenient folded formats speed up your sample preparation
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.